Effect of long-term Insulin on glycemia control in critically ill patients admitted to intensive care unit

Effect of glargine Insulin on glycemia control in critically ill patients admitted to intensive care unit

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201608182582N14

Enrollment

Registered

2016-11-07

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Insulin-dependent diabetes mellitus

Interventions

Intervention 1: intervention group: patients will receive 10 IU Glargine daily in addition to regular insulin therapy, subcutaneously. Intervention 2: control group: All patients will receive routine

Treatment - Drugs

intervention group: patients will receive 10 IU Glargine daily in addition to regular insulin therapy, subcutaneously.

control group: All patients will receive routine regular insulin therapy which is Regular insulin infusion. The regular insulin (Actrapid HM, NOVO Nordisk, Denmark) will be infused via central vain ca

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All admitted diabetic patients in ICU Exclusion: age under 18 y/o; sensitivity to insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood Glucose. Timepoint: every one hours. Method of measurement: Laboratory.	—

Secondary

Measure	Time frame
Mortality. Timepoint: Daily. Method of measurement: counting.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolreza Naghizadeh

Tabriz University of Medical sciences

abdolreza_naghizadeh@yahoo.com+98 41 3333 8413

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026